Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 8/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | ITGAL | P20701 | 1/20 | 0.43 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22091651 | 0.93 | AGTR2 (0.47) | AGTR2BDKRB2CARM1PRMT6MMP9 | |
| SCHEMBL27224005 | 0.82 | AGTR2 (0.59) | AGTR2BDKRB2MMP9 | |
| SCHEMBL9033443 | 0.82 | AGTR2 (0.59) | AGTR2BDKRB2MMP9 | |
| SCHEMBL9033440 | 0.82 | AGTR2 (0.59) | AGTR2BDKRB2MMP9 | |
| SCHEMBL3784713 | 0.82 | AGTR2 (0.59) | AGTR2BDKRB2MMP9 | |
| SCHEMBL9603360 | 0.82 | AGTR2 (0.59) | AGTR2BDKRB2MMP9 | |
| SCHEMBL17099295 | 0.82 | AGTR2 (0.47) | NAAAAGTR2BDKRB2MMP9 | |
| SCHEMBL17099064 | 0.79 | AGTR2 (0.44) | NAAAAGTR2BDKRB2MMP9 | |
| SCHEMBL8227117 | 0.78 | USP30 (0.43) | ITGB2ICAM1ITGALCARM1PRMT6 | |
| SCHEMBL4307660 | 0.78 | CACNA1B (0.40) | AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314062-B2 | Macrocyclic compounds as antiviral agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-11-20 | — | — | US | disclosed |
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | NAAA 3527/4885AGTR2 822/4885ITGB2 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.